• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Policy, Organisation and…
  • Quality of Life

Capturing the Broader Value of Antibiotics

STEDI Roadmap
Read more
  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Innovation for Health System Efficiency and Improvement

Report picture
Read more
  • Drug Development/R&D
  • Value, Affordability, and…
  • Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

6
Read more
  • Antimicrobial Resistance (AMR)
  • Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Proposal for a Novel Antimicrobial  Subscription
Read more
  • Health Care Systems
  • Policy, Organisation and…
  • Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Prev web
Read more
  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 14th June 2012

New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?

Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento. In this publication, he explores whether R&D productivity in the pharmaceutical industry has declined and, if so, why. Just published are…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Trends in attrition rates of drug development projects

Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento. In this publication, he explores whether R&D productivity in the pharmaceutical industry has declined and, if so, why.

Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento.  In this publication, he explores whether R&D productivity in the pharmaceutical industry has declined and, if so, why[1].

Launches of new products, Prof Riccaboni notes, have remained at about the same number per year since 2000 and have remained at a level lower than during the 1990s.  He identifies two reasons for this.  First, development times (patent filing to market launch) have increased markedly.  From an average of 9.7 years in the 1990s, development times increased to an average of 13.9 years after 2000.  Second, “attrition rates”, i.e. the percentage of R&D projects that are discontinued, have increased – and particularly in Phases 2 and 3.

Trends in attrition rates of drug development projects

Trends in attrition rates of drug development projects

  Several reasons for these trends are identified by Prof Riccaboni:

  1. The “fishing-out effect” means that the “easy” diseases have been addressed and today’s more complicated targets carry a higher risk of failure
  2. The pharmaceutical industry is experiencing a “gestation lag”, which occurs when a radical change in technological capabilities (i.e. the molecular biology revolution) requires a corresponding shift in research approach
  3. More complex science requires the assembly and management of larger teams with a greater range of expertise
  4. A mix of regulatory requirements and marketing changes are making competition tougher, increasing the likelihood that projects will be discontinued
  5. The threshold of knowledge required to shift R&D to new targets is higher and requires more time to acquire and employ

In this Seminar Briefing, Prof Riccaboni tracks the shift in the composition of R&D portfolios towards more complex and higher risk areas of research. For example, comparing the R&D portfolio composition from 1990-1999 to that of 2000-2007 shows “an 8% increase in cancer research projects and a 4.57% decrease in the cardiovascular area.”  Also increasing is research in anti-neoplastic agents (6.9%), neurological diseases (1.1%), and alimentary tract metabolism (1.6%).  R&D in all other areas has been declining.  The reasons for the shifts, according to Prof Riccaboni, are a mix of company strategy,  i.e. deciding that higher potential rewards are worth higher risk, and public incentives, e.g. allowing only “breakthrough” drugs to be eligible for higher pricing.

In comparing R&D performance of companies based in the US and Europe, Prof Riccaboni also identifies a set of “global” companies that seek out new opportunities and talented people outside the countries in which they are headquartered. He finds that, overall, the R&D productivity of these global companies is highest. With respect to sales, “the market value of NMEs for European companies is far lower than the market value for US companies even after controlling for a number of variables”, he notes, but he found “no difference between the market value of drugs produced by US companies and that of global companies that do most of their research in the US.”

Download Riccaboni, M. (2012) Is there a productivity crisis in pharmaceutical R&D? Seminar Briefing. 11. London: Office of Health Economics.

 


[1]Prof Riccaboni drew extensively in the seminar from: Pammolli, F., Magazzini, L. and Riccaboni, M. (2011) The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery. 10, 428-438.  

 

  • Drug Development/R&D
  • Economics of Innovation
  • Innovation

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!